Related Experiment Video

Updated: Dec 13, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

920

[Highlights of PAPR Inhibitors in Small Cell Lung Cancer]

Shuang Zhang1, Jingjing Liu1, Changliang Yang1

  • 1Department of Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun 130012, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|August 6, 2020
PubMed

Insights

Poly (ADP-ribose) polymerase (PARP) inhibitors show promise as a targeted therapy for small cell lung cancer (SCLC), potentially offering a breakthrough for precision medicine despite current limitations.

Area of Science:

  • Oncology
  • Genetics

Background:

  • Small cell lung cancer (SCLC) presents significant treatment challenges due to early metastasis, relapse, and resistance.
  • Current therapeutic strategies for SCLC are limited, necessitating novel treatment approaches.

Purpose of the Study:

  • To explore the potential of poly (ADP-ribose) polymerase (PARP) inhibitors as a targeted therapy for SCLC.
  • To review the current research landscape of PARP inhibitors in SCLC treatment, including combinations and predictive markers.

Main Methods:

  • Review of existing studies on PARP inhibitors in various SCLC treatment settings (first-line, recurrent, maintenance).
  • Exploration of research into predictive markers for PARP inhibitor efficacy in SCLC.

Main Results:

  • PARP inhibitors are a research hotspot for SCLC targeted therapy due to genomic instability and chemotherapy sensitivity.
  • Studies have investigated PARP inhibitors in combination with other treatments and explored predictive markers, though results are currently limited and inconsistent.

Conclusions:

  • Despite limited current data and inconsistent predictive markers, PARP inhibitors represent a potential breakthrough for precision medicine in SCLC.
  • Further research is needed to optimize PARP inhibitor therapy and identify reliable predictive biomarkers for SCLC treatment.
Keywords:
Lung neoplasmsPARP inhibitor

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.9K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.9K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
348
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K